Xanthine oxidase-IN-4
Modify Date: 2024-01-03 17:18:38
Xanthine oxidase-IN-4 structure
|
Common Name | Xanthine oxidase-IN-4 | ||
|---|---|---|---|---|
| CAS Number | 2642137-96-8 | Molecular Weight | 295.30 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H13N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Xanthine oxidase-IN-4Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research[1]. |
| Name | Xanthine oxidase-IN-4 |
|---|
| Description | Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.039 μM (xanthine oxidase)[1] |
| In Vitro | Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC50 of 0.039 μM, and Ki of 0.0037 μM[1]. |
| In Vivo | Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid[1]. Animal Model: Sprague-Dawley rats (Six weeks, male, 180-200g, six groups)[1] Dosage: 10 mg/kg Administration: Intragastrically, once Result: Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%. |
| References |
| Molecular Formula | C15H13N5O2 |
|---|---|
| Molecular Weight | 295.30 |